Articles tagged with Prostate Cancer
Researchers at UCLA Health Jonsson Comprehensive Cancer Center receive $1.7M grant to advance CAR T-cell therapies for metastatic castration-resistant prostate cancer. They will investigate a new approach combining engineered nanovial technology with single-cell analysis to rapidly evaluate and optimize dual-targeted CAR T-cell therapies.
A new blood test, Stockholm3, detected significantly more aggressive prostate cancers than the PSA test without increasing unnecessary follow-ups. The study shows that Stockholm3 identifies 90% of aggressive cancer cases, compared to 74% for PSA.
A new study found that conversations about prostate cancer screening are uncommon in primary care visits but lead to higher screening rates when they do occur. The study suggests a gap between national guidelines and clinical practice, highlighting the importance of shared decision-making for individualized care.
Researchers at UT MD Anderson Cancer Center have made significant advances in understanding cancer biology, developing AI-powered atlas of tertiary lymphoid structures as prognostic biomarkers, and uncovering drivers of resistance to KRAS inhibitors. Additionally, they have discovered a molecular pathway that drives stressed cells to b...
A recent study analyzing 670,000 patients found a higher frequency of advanced disease among non-white men and differences in access to modern therapies. The study also revealed significant racial inequalities in treatment costs, with white patients receiving 16.2% more funding.
A phase 3 clinical trial found that apalutamide plus hormone therapy before and after surgery reduced the risk of metastasis or death by 20% compared to hormone therapy alone. Patients treated with this regimen had a higher pathologic response rate and experienced delayed subsequent therapy.
Researchers at Columbia University Irving Medical Center have identified Sirtuin 1 as a key driver of neuroendocrine prostate cancer, an aggressive form of the disease. Genetic or pharmacological inhibition of Sirtuin 1 prevents tumor growth in mice and lays the groundwork for future clinical studies aimed at developing new treatments.
A new poll by Physicians Committee for Responsible Medicine finds that most men consider a carnivore diet to be 'masculine' and would change their diet if it put their health at risk. The survey also found that consuming meat is linked to an increased risk of heart disease, erectile dysfunction, and reduced fertility.
Researchers discovered that androgen receptor signaling acts as a transcriptional repressor of liver receptor homolog-1 (LRH-1) in prostate cancer. This finding reveals a previously unknown mechanism of gene regulation and highlights the potential for targeting this axis to manage advanced prostate cancer.
Research finds ceramide metabolism differences between Black and white individuals with metastatic castration-resistant prostate cancer influence treatment outcomes. Genetic ancestry-related variants affect ceramide levels and ratios, which promote cell survival or death.
Researchers from Mass General Brigham Cancer Institute presented various studies on cancer treatments, including the efficacy of lung cancer drug neladalkib and a psychosocial digital app for patients with multiple myeloma. An electronic frailty index was also used to identify high-risk older adults receiving CAR-T cell therapy.
Researchers from ECOG-ACRIN Cancer Research Group will present updated outcomes from the STAMP study on Merkel cell carcinoma, primary results from studies in glioblastoma and non-small cell lung cancer, and emerging approaches in precision oncology. AI-driven insights from the TAILORx breast cancer trial will also be showcased.
Dropping the cancer label from grade group (GG)1 prostate disease redefines it as a precancerous lesion, leading to a net reduction in estimated prostate cancer deaths. This relabeling strategy may have minimal impact on screening rates.
Researchers discovered a new gene expression signature linked to prolonged overall survival in patients with metastatic castration-resistant prostate cancer who responded to combined immune checkpoint inhibitors. The biomarker has the potential to help identify patients most likely to benefit from this treatment combination.
Researchers found that a common asthma drug can help fight aggressive cancers by blocking the CysLTR1 molecule. The study used mouse models and human tissue samples to demonstrate its potential in treating triple-negative breast cancer and other tough tumors.
A study published by the European Society for Radiotherapy and Oncology found that delivering radiotherapy in just two sessions over eight days is safe and effective for treating prostate cancer. The treatment had no additional side effects compared to the standard five doses, making it a convenient option for patients.
A randomized clinical trial found that testosterone treatment significantly improved sexual activity, sexual desire, and quality of life scores in men after prostate cancer surgery. The treatment also improved body composition and aerobic performance without increasing the risk of biochemical recurrence.
At ASCO 2026, City of Hope experts will present research on innovative treatments for various types of cancer. Their findings include the efficacy and safety of immunotherapy combinations, as well as the potential use of CBM588 to enhance immune checkpoint blockade in metastatic renal cell carcinoma.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
The new NCCN Guidelines for Patients: Prostate Cancer Screening provide a comprehensive guide to evidence-based recommendations for age-specific screening. The guidelines aim to balance the benefits of early detection with the risks of unnecessary procedures, emphasizing the importance of personalized care and monitoring.
Researchers at the University of British Columbia have developed a new method to target intrinsically disordered proteins, which are difficult to treat with medication. The approach has shown promise in slowing prostate cancer growth and could lead to new treatments for various diseases.
A new study found that prostate cancer overdiagnosis increases with age, with low rates in younger men and high rates in older men. The study suggests that targeted PSA testing or screening policies for men in their 50s and early 60s may be more effective.
New research suggests that federal housing assistance may lead to better two-year survival chances among older men with prostate cancer. The study found a 12% lower risk of death in men who received housing assistance compared to those without it.
Research finds PDX1 gene plays a tumor-promoting role in human PCa cells by influencing metabolic pathways. The study identifies PDX1 as differentially hypermethylated in prostate cancer tissues, contributing to its aggressive characteristics.
A new randomized clinical trial found that men with localized, intermediate-risk prostate cancer recovered faster and experienced less short-term impact on their daily lives when treated with MRI-guided, transurethral ultrasound ablation (TULSA) compared to robotic prostate surgery. TULSA resulted in less blood loss, shorter hospital s...
The European Association of Nuclear Medicine (EANM) has joined the EMUC26 congress to promote nuclear medicine expertise in urological cancers. The event will bring together healthcare professionals from various disciplines to discuss current practices and emerging innovations.
Researchers reveal that immune system's T cells travel to the prostate to provide long-term protection against infections. Harnessing these disease-fighting cells could lead to new therapies for prostate cancer and inflammatory conditions.
A new study found that metformin raises levels of N-lactoyl-phenylalanine, a molecule tied to energy balance and weight control, in men with prostate cancer. This finding suggests metformin could help counter metabolic strain caused by hormone therapy, which often limits physical activity.
Researchers developed first-in-class dual HIF inhibitors that, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice. The drugs target HIF-1/2 transcription factors, which are key regulators of cancer progression.
Researchers found that targeting MD2 could reduce tumor growth in a mouse model of prostate cancer bone metastasis. High MD2 expression was associated with metastasis, immune suppression, and increased resistance to PARP inhibitor therapy.
Researchers at VCU Massey Comprehensive Cancer Center developed a targeted therapy that effectively prevents prostate tumors from spreading to the bone. The small molecule inhibitor IVMT-Rx-4 blocks the function of MDA-9/Syntenin, preventing tumor growth and improving survival in models with bone metastasis.
A new study shows that PSMA therapy can delay the need for hormone therapy in prostate cancer patients by an average of 20 months. The therapy is effective in earlier stages of the disease, improving survival and quality of life for approximately two out of three patients.
Six Weill Cornell Medicine researchers have been awarded Young Investigator Awards by the Prostate Cancer Foundation to investigate prostate cancer at a molecular level and develop new therapies. Drs. Bashir Al Hussein Al Awamlh, Cheuk Man Cherie Au, Lise Brault, Xuanrong Chen, Kevin Kensler, and Silvia Rodrigues will focus on improvin...
A new platform called ATLAS enables researchers to generate large quantities of cancer cell clusters that accurately model metastasis. Using ATLAS, the Rice team gained insights into the mechanisms that enable cancer clusters to survive in the bloodstream during the metastatic process.
Scientists have identified a new cell type and discovered that many normal-looking prostate cells harbor cancer-related changes. The study's findings could lead to new risk factors, earlier detection methods, and more targeted therapies for patients at high risk of aggressive disease.
A large clinical trial led by UCL researchers has shown that hormone patches are as effective as injections in controlling locally advanced prostate cancer. The patches cause fewer side effects, including hot flushes and breast tissue swelling, while improving quality of life for men with the condition.
A study found CREB5 regulates basal and SCL transcriptional programs and tumor-forming phenotypes in prostate cancer, suggesting a central role in aggressive prostate cancer. Disrupting CREB5-regulated pathways may improve therapeutic responses in advanced disease.
UCLA researchers identified a key protein, E2F3, essential for survival in cancer cells lacking the protective gene RB. Blocking E2F3 effectively halted tumor growth, offering a new strategy for treating aggressive cancers.
Bidkar aims to develop a novel CD46-targeted radiotheranostic platform to treat metastatic castration-resistant prostate cancer. His proposal focuses on overcoming tumor heterogeneity and improving treatment outcomes.
Researchers engineered supercharged T cells that can recognize and kill prostate cancer cells more effectively. By fine-tuning how they physically interact with tumor cells, the T cells form a stronger bond, allowing them to deliver a targeted immune response without damaging healthy tissue.
Researchers compare prostate cancer screening to breast cancer screening, finding similarities in identifying significant cancers and reducing mortality. The study suggests that prostate cancer screening should be reconsidered, offering benefits over harms, and highlights the need for further analysis on costs.
The Sylvester Cancer Tip Sheet for March 2026 highlights the importance of genetic testing for cancer risk assessment. Researchers have made significant progress in developing new treatments, including mRNA-based immunotherapy for colorectal and pancreatic cancers. Additionally, the Dolphins Cancer Challenge has surpassed $100 million ...
A new imaging test, PSMA PET/CT scan, has been shown to safely reduce the number of biopsies needed for suspected prostate cancer, with no harm to patients. The PRIMARY2 trial found that the scan could identify low-risk patients who did not need a biopsy, while targeting suspicious areas for those who did.
A new study found that MYC amplification in metastatic prostate cancer is associated with reduced tumor immunogenicity, making it harder for the immune system to detect and attack the tumor. This reduction in immunogenicity was linked to poorer progression-free survival outcomes in patients with MYC-amplified tumors.
Research presented at EAU26 confirms that prostate cancer screening leads to a reduction in mortality, but also detects cancers that would otherwise remain undetected. The study's findings suggest that using MRI in prostate cancer screening can reduce overdiagnosis and unnecessary biopsies.
Researchers at Weill Cornell Medicine have identified the FOXJ1 gene as a key player in chemotherapy resistance in prostate cancer. The study found that increased FOXJ1 levels in tumors can make cancer cells less responsive to taxane chemotherapy, leading to poorer outcomes for patients.
A study by the University of Texas M. D. Anderson Cancer Center found that men with low testosterone levels are 60% more likely to have their prostate cancer progress to a more aggressive state during surveillance. Low testosterone may serve as a useful clinical marker to guide treatment and surveillance strategies.
A study of 2,997 adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and anticoagulants found no increased risks of bleeding or clotting. The findings contradict previous lab results and provide reassurance for clinicians and patients managing anticoagulation alongside modern prostate cancer treatments.
Researchers at Weill Cornell Medicine will develop an AI system to identify patients with early signs of treatment-resistant prostate cancer. The project aims to improve clinical trials by predicting treatment outcomes and avoiding ineffective treatments for patients with specific tumor subtypes.
Researchers developed a new immunotherapy strategy by pairing next-generation therapy with standard hormone therapy before surgery, reducing Treg levels inside tumors and improving patient outcomes. The study provides clinical evidence for the effectiveness of engineered anti-CTLA-4 therapies in early-stage prostate cancer treatment.
A new UCLA study suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with low PSA levels. However, men with higher PSA levels before radiation may see modest improvements in survival and metastasis-free survival.
Researchers found that tumors with androgen receptor alterations experienced poorer outcomes, shorter overall survival, and earlier need for subsequent therapy. Serial liquid biopsies revealed real-time molecular changes linked to treatment pressure.
A new study has discovered microplastics in nine out of ten patients with prostate cancer, with higher levels found in tumor tissue than noncancerous tissue. The findings suggest that microplastic exposure may be a risk factor for prostate cancer.